M&A Deal Summary

Biocon Acquires Viatris - Biosimilars

On February 28, 2022, Biocon acquired life science company Viatris - Biosimilars from Viatris for 3.3B USD

Acquisition Highlights
  • This is Biocon’s 1st transaction in the Life Science sector.
  • This is Biocon’s largest (disclosed) transaction.
  • This is Biocon’s 2nd transaction in the United States.
  • This is Biocon’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2022-02-28
Target Viatris - Biosimilars
Sector Life Science
Buyer(s) Biocon
Sellers(s) Viatris
Deal Type Divestiture
Deal Value 3.3B USD

Target

Viatris - Biosimilars

Canonsburg, Pennsylvania, United States
Viatris' Biosimilars provides affordable access to patients through its portfolio in diabetes, oncology, immunology, and other non-communicable diseases. Viatris' Biosimilars is based in Canonsburg, Pennsylvania.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Biocon

Bengaluru, India
Category Company
Founded 1978
Sector Healthcare Services
Employees16,315
Revenue 142.0B INR (2024)
DESCRIPTION

Biocon develops and sells biotechnology products for the pharmaceutical sector in India and internationally. Biocon was founded in 1978 and is based in Bengaluru, India.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 2 of 2
Year (2022) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-04-17 Nobex

Research Triangle Park, North Carolina, United States

Nobex Corporation was acquired by Biocon Ltd. Nobex Corporation, a drug development company, develops oral peptide therapeutics in the United States.

Buy -

Seller(S) 1

SELLER

Viatris

Canonsburg, Pennsylvania, United States
Category Company
Founded 1961
Sector Life Science
Employees33,000
Revenue 15.4B USD (2023)
DESCRIPTION

Viatris is a generic and specialty pharmaceutical company. Viatris offers the industry's broadest and highest quality product portfolios, a robust product pipeline, and a global commercial footprint through operations in more than 90 countries. Viatris was founded in 1961 and is based in Canonsburg, Pennsylvania.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 3
Type (Divestiture) 1 of 3
State (Pennsylvania) 1 of 3
Country (United States) 1 of 3
Year (2022) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-08 Aspen Pharmacare Holdings - Thrombosis Business

United Kingdom

Aspen Pharmacare's Thrombosis Business is a global offering comprised largely of a broad range of specialist injectable anticoagulants. Aspen's portfolio also includes Orgaran which is a heparin derivative (heparinoid) indicated for the treatment of HIT. HIT is an adverse reaction occurring in a limited number of patients undergoing heparin related therapy. It offers healthcare providers the advantage of a single supplier that addresses broad clinical needs and thus ensures the optimal care of patients at risk of thrombosis.

Buy €642M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-07-03 Viatris - Over the Counter Business

Canonsburg, Pennsylvania, United States

Viatris - Over the Counter (OTC) Business is a global healthcare company.

Sell -
Mergr

Product

Company

Legal